NCT03365765

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Huashan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will focus on postoperative patients of stage IIIB or stage IIIC colorectal cancer. These patients will start to accept chemotherapy in 3-4 weeks after operation, these patients were randomly divided into two groups, one group will accept adjuvant chemotherapy of mFOLFOX6; another group will use mFOLFOX6 combined with apatinib. The efficacy and safety of adjuvant chemotherapy will be compared between the two groups. Disease-free survival, overall survival, incidence of adverse reaction of chemotherapy and postoperative quality of life will be recorded.

Conditions

• Apatinib

Interventions

Type	Name	Description
DRUG	Apatinib	Apatinib tablet
DRUG	Oxaliplatin	Oxaliplatin Intravenous
DRUG	5-fluorouracil	5-fluorouracil Intravenous

Timeline

• Start date: 2018-02-12
• Primary completion: 2022-12-22
• Completion: 2022-12-31
• First posted: 2017-12-07
• Last updated: 2023-02-14

Locations

1 site across 1 country: China